This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Emergent's (EBS) Narcan Gets OTC Status for Opioid Overdose
by Zacks Equity Research
Following the FDA approval, Emergent's (EBS) Narcan nasal spray becomes the first OTC product approved for emergency treatment of opioid overdose. This product will be made available by late summer of this year.
Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study
by Zacks Equity Research
Preliminary data from an ongoing mid-stage study shows that treatment with Biomea's (BMEA) lead candidate demonstrated a robust glucose-lowering response in patients with type II diabetes.
Is CRISPR Therapeutics (CRSP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how CRISPR Therapeutics AG (CRSP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer
by Zacks Equity Research
Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma.
Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe
by Zacks Equity Research
Amicus (FOLD) receives approval from the European Commission to treat the adult late-onset Pompe disease with Pombiliti (cipaglucosidase alfa).
Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug
by Zacks Equity Research
Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan
by Zacks Equity Research
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
by Zacks Equity Research
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.
CRISPR Therapeutics AG (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
by Zacks Equity Research
Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.
Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA
by Zacks Equity Research
Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the treatment of hereditary angioedema.
Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals
by Zacks Equity Research
CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals are part of the Zacks Industry Outlook article.
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $45.06, marking a +1.35% move from the previous day.
Here's Why You Should Add CRISPR Stock to Your Portfolio
by Zacks Equity Research
CRISPR Therapeutics (CRSP), a top-ranked stock at present, is developing its lead pipeline candidate to treat TDT and SCD.
4 Biotech Stocks to Consider for Your Portfolio in 2023
by Zacks Equity Research
New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
by Zacks Equity Research
Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates
by Zacks Equity Research
Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.
Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences
by Zacks Equity Research
Jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake in the company.
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges
by Zacks Equity Research
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.51%: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $44.92, moving -0.51% from the previous trading session.
Alkermes (ALKS) Stock Up 15% in Six Months: Here's Why
by Zacks Equity Research
Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.
Novo Nordisk (NVO) Follows Lilly, to Cut Insulin Prices by 75%
by Zacks Equity Research
Novo Nordisk (NVO) plans to lower prices of several pre-filled insulin pens and vials by up to 75% in the United States. However, the company plans not to start this until January 2024.
AstraZeneca (AZN) Stock Up 5% in a Year: What Awaits in 2023?
by Zacks Equity Research
AstraZeneca (AZN) expects total revenues to increase in the low-to-mid single-digit percentage in 2023 at CER.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $45.15 in the latest trading session, marking a -1.25% move from the prior day.
Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals
by Zacks Equity Research
Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.